BALTIMORE, MARYLAND (October 29, 2014) – Camden Partners is pleased to announce its new investment in Paragon Bioservices, Inc., one of the nation’s leading contract research and manufacturing organizations focused on biologics. Camden Partners co-led this Series A financing with NewSpring Capital.
Camden Partners will serve on the Company’s board of directors alongside Chief Executive Officer Marco Chacon, Ph.D. and Kapila Ratnam, Ph.D. of NewSpring Capital.
New Paragon management team members include Chief Operating Officer Peter Buzy, former Chief Financial Officer of Martek Biosciences (acquired by Royal DSM for $1.1B in 2011).
For more information, go to Paragon’s press release at http://prn.to/1wzfNFw.
About Paragon Bioservices, Inc.
Baltimore-based Paragon Bioservices focuses on the development and manufacturing of biopharmaceutical protein drugs. As a nationally-recognized contract manufacturing organization (CMO) service provider, Paragon is positioned to capitalize on industry trends-including consolidation in the pharmaceutical industry, programmatic outsourcing and the looming National Preparedness imperative. With 20 years in the business, Paragon’s scientists, engineers, quality systems personnel and project managers have many years of experience working with biologics-from research and process development services to GMP manufacturing for clinical trials and eventual commercial launch. For more information, please go to www.paragonbioservices.com.
About Camden Partners
Camden Partners is a Baltimore-based private equity firm focused on seed and growth stage investments in healthcare, education, technology and business services companies. For more information, please go to: www.camdenpartners.com.